INTRODUCTION
T he largeness usage and the most important therapy result have antitumor preparation as Gemcitabin, Cisplatina, Merthrotrexat, Adriamicin, Vinblastin, Taxol, 5-Fluoracil. Previous experience claims that monotherapy gives lower impartial answer percentage and shorter answer duration, compare with polyhemiotherapy. Numerous chemotherapeutical protocol begun by combination of two or more antitumor preparation usage in invasive bladder tumor therapy.
By M-VAC protocol -methotrexat, vinblastin, adriamicin, cisplatin -is effect positive answer in about 50% and superiority comparing with the chemotherapeutical protocols is shown. The fundamental deficiency of chemotherapy, according to M-VAC protocol, is significant level of toxicity, mielosupresion, nephrotoxicity, mucositis, vomiting.
Evaluations of antineoplastic preparation therapy performance are based on application of criterion that is ascribed by several leading international organizations against bladder carcinoma.
Answer after provided diagnostic procedures realization estimate as: a) complete response/CR/-Complete disappearance of clinical signs in a period longer than one month. b) partial response/PR/-More than 50% reduction of tumor lesions, and in a meantime without new appearance. c) stable disease /SD/-Less than 50% reduction of tumor lesions and without new appearance. d) disease progresion /PD/-Appiriance of a new tumor lesions or augmentation of existent more than 25% e) response duration-Time interval from the beginning of therapy conduction till appearance of disease progression f) entire surviving length-Time managed from the beginning of the treatment till the finally outcome, the last control. rezime sion is founded (T3b) and loco regional infiltration neighboring structures (T4). Among them were those who were after surgical treatment done before, histology verified tumor changed lgl (N+) and those in whom were by clinical procedures founded metastatic deposits in distant organs. Estimation of the stage means histology verification of the tumor and degree of the expansion into the bladder, and also, condition of regional lymphoid glands, gained by surgical dissection. Visceral organs condition is estimated by ultrasound and lungs radyography. In the unperpicous cases the additional diagnostic procedures (CT, MRI, sceletal scintigraphy) are used.
MATERIAL AND METHODS

In
Chemotherapy was stationary done, and in that ambulance. Administration included four circle of time, every 28 days. The cycle was divided into two parts, 1. and 14. day.
Before the administration, intravenous hidratation of the patient was done. First day intravenous were given 120 mg Cisplatin, 50 mg Doxorubicin, 50 mg Methotrexate, 0,5 mg Vincristin.
Fortheenth day, with previous intravenous hidratation were given 50 mg Doxorubicina, 50 mg Methotrexata, 0,5 mg Vincristina.
Before the therapy, in all patients were done blood analysis and blood urea and creatinine.
The condition for therapy application was-number of leucocytes higher than 2500, trombocytes higher then 100 000, haemoglobin higher then 10 gr/L, and serum creatinine lover then 150 mmol/L. In the case of the surrender, the therapy was suspended or delied.
Because of toxic effects appearance, especially myelosupresion and nausea, all patients were treated by supportive therapy.
Estimate of therapy reply was perceived by ultrasound, CT, lung RTG, every two months, and after 6 months, every three months.
As a paramethars of therapy effect are followed a period of time till the appearance of disease progression and survival time after the therapy.
According to proposition of several international organizations against bladder carcinoma, the result of the therapy was valuated as positive reply, or total of complete and partial replies (CR+PR), absence of therapy reply and disease progression. Also, was analyze toxic degree and complication caused by chemotherapy administration. Table 1 . are shown demographic and clinical characteristics of the patients, with progressive bladder carcinoma, that were treated by systemic chemotherapy according to M-VAC protocol. (Table 1) In thirty-three out of 46 patients, responded to the treatment , were done cystectomy, but in nine patients only surgical exploration and biopsy. Four patients were not surgical treated because of deposit in distant organs. They were treated only by systemic chemotherapy. After the surgical treatment, in twenty patients histology was verify malignant cells in lymphoid glands. Average follow up was 21,7 months (4,6-72,3). 
RESULTS
On
TOXICITY
Toxicity was generally mild tolerated. Grade III leucopenia was found in 2 patients. In six patients because of anemia were given blood transfusions. (Table 2) 
SENSIBILITY
In 17 patients (37%/)were realized positive response to the treatment, in 3 patients complete response (CR 6,5%), and partial response in 14 patients (PR 30,5 %). Ten patients had stable disease, while in 19 were shown progressive disease. (Table 3 .)
SURVIVAL
The median time to progression for all patients was 22,9 (4,6-68,7) months while the median survival was 26,5 (4,3-72,5%) months. Patients who responded completely (62,9 months) had a significantly longer median survival compared to those who responded partially (15,7 months). Patients with stable disease had a 17,2 month median survival and those with progressive disease only 10,6 months.
These differences were highly significant (p<0,001).
DISCUSSION
Systemic chemotherapy is of importance in progressive bladder carcinoma treatment. The combination chemotherapy has great application in everyday urology practice. Recidive rate after the radical cystectomy is about 20% in T2-T3, No patients, but in T4, N+ group is 80-90%.
The main aim of the adjuvant chemotherapy is to make the surgical results better, and the survival longer.
The Italian authors cite significant frequent five-year survival in T2-T4 patients without nodal metastasis, about 60%, comparing with patient with metastasis in lymphoid glands, only 4%.
Sternberg and coll. 7 cite that the adjuvant chemotherapy in patients with metastatic changed lymph glands gives better therapy response and longer survival, coppering with patients with locoregional infiltration and visceral metastasy.
In patients in metastatic disease phase, systemic chemotherapy means optimal therapy access and the only possibility that shows longer survival for those patients. In our investigation the survival in patient with visceral metastasis was 8,8 months.
Logothetis and coll. 4 in a study founded median survival about 8,4 months in patients in metastatic disease phase , treated by CISCA protocol, comparing with those who were under the chemotherapy with M-VAC protocol had a survival rate of 11,4 months.
Memorial Sloan Kettering Cancer Center in a follow-up study had a median survival of 13,1 months in metasatic disease phase, treated by chemotherapy according to M-VAC protocol. Their conclusions claim that the therapy is significantly efficient in nodal metastasis than in patients with visceral one. Br. 4
The side effects that chemotherapy case are important limiting factor in its application , and it is a reason why the dose modification and application modalities are very often oncology doubt.
The most frequent problems are hematological toxicity and nausea with vomiting.
In our study the most frequent symptom of acute therapy toxicity was leucopenia Gr I and II, 67%. In two patients were found great degree of acute toxicity Gr IImyeosupresion.
Gospodarewich and coll. 10 found letal result cased by M-VAC chemotherapy toxicity, in 4% treated patients.
CONCLUSIONS
The main determinating factor of disease progression and survival was therapy response. The positive response is within the competency of the partial response (84%). The survival was significant longer in patients that gain positive response, comparing with those where response omit.
Patients with local progressive carcinomas and those with loco regional dissemination, showed much longer survival than patients with distant metastasis.
The toxicity of the chemotherapy was good tolerated and there were no case with acute toxicology gradus IV.
SUMMARY HEMIOTERAPIJE PO M-VAC PROTOKOLU U TRET-MANU UZNAPREDOVALIH KARCINOMA MOKRA]NE BE[IKE
Le~enje invazivnih tumora mokra}ne be{ike predstavlja slo'en terapijski postupak koji podrazumeva primenu hirur{kih i nehirur{kih procedura. I pored sprovedenog radikalnog hirur{kog tretmana, koji predstavlja "zlatni standard" u le~enju invazivnih tumora mokra}ne be{ike, izmedju 30-40% bolesnika razvija metastaze u daljem toku bolesti i ima lo{u prognozu.
U terapiji invazivnih tumora mokra}ne be{ike poseban akcenat se stavlja na sistemsku hemioterapiju, ~iji je osnovni cilj da popravi rezultate hirur{kog le~enja. Ova terapijska opcija neretko predstavlja i jedini modalitet u le~enju tumora mokra}ne be{ike, kao na primer u diseminovanoj fazi bolesti.
Adjuvantna hemioterapija ima za cilj da popravi rezultate hirur{kog le~enja tamo gde postoji veliki rizik od nastanka recidiva.
Kao rizici za nastanak recidiva navode se: a) limfati~na i vaskularna invazija u primarnom tumoru; b) ekstravezikalna ekstenzija tumora (T3b); c) zahvatanja tumorom okolnih struktura (T4); d) nalaz pozitivnih lgl (N+);. Nakon radikalne cistektomije zbog tumora (T3b, T4) visokog stepena maligniteta, nadjena je ucestalost pozitivnih lgl u oko 40-60%. Pacijenti sa pozitivnim lgl imaju lo{u prognozu i oko 17 % pre'ivi dve godine, a samo njih 7% pre'ivi pet godina.
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